Clostridium difficile-Associated Diarrhea and PPI Therapy
Clostridium difficile-Associated Diarrhea and PPI Therapy
PPI use increases the risk for CDAD significantly. Future studies should focus on evaluating the dosage and duration of PPI use and the risk of CDAD and its recurrence. Further high-quality, prospective trials focusing on duration of therapy and dose of therapy are further warranted to show the strength of this association.
Conclusion
PPI use increases the risk for CDAD significantly. Future studies should focus on evaluating the dosage and duration of PPI use and the risk of CDAD and its recurrence. Further high-quality, prospective trials focusing on duration of therapy and dose of therapy are further warranted to show the strength of this association.